Argo Biopharmaceutical Co Ltd, a clinical-stage small interfering RNA (siRNA) therapeutics company, announced on Monday that the first participant has been dosed in its Phase I study of BW-41012, an investigational siRNA therapy targeting factor XI (FXI) for the prevention of thromboembolic diseases.

Earlier in July, the company received Investigational New Drug (IND) approval from the China National Medical Products Administration (NMPA) for BW-41012, further advancing its global clinical development.

According to Argo Biopharma, BW-41012 is an siRNA therapeutic that targets FXI mRNA. The Phase I study is a randomised, double-blind, placebo-controlled, single ascending dose trial designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneous administration of BW-41012 in healthy volunteers in Australia. The study will assess safety and biomarkers of biological activity, including clinical laboratory parameters, vital signs, electrocardiogram (ECG) measurements, FXI activity, and FXI antigen levels, to characterise the pharmacological profile of BW-41012 and support its further clinical development for the treatment of thromboembolic diseases.